SCHEMBL8947080

SCHEMBL8947080

CC(C)=CCc1ccccc1OC(Cc1ccccc1)CC(P(=O)(O)O)S(=O)(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 6/20 0.35
AKR1C2 P52895 6/20 0.35
AKR1C4 P17516 1/20 0.33
LAP3 P28838 4/20 0.33
ANPEP P15144 1/20 0.33
PIN1 Q13526 1/20 0.32
ACP3 P15309 1/20 0.32
CRHBP P24387 1/20 0.31
PPARG P37231 1/20 0.31
PPARD Q03181 1/20 0.31
PPARA Q07869 1/20 0.31
CRHR2 Q13324 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
APAF1 O14727 1/20 0.31
TDP2 O95551 1/20 0.31
NSD2 O96028 1/20 0.31
CYP1A2 P05177 1/20 0.31
POLB P06746 1/20 0.31
CYP2D6 P10635 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9167366 0.88 ADRA2C (0.38) AKR1C3AKR1C2LAP3ANPEPACP3
SCHEMBL8625379 0.84 PPARA (0.38) LAP3ANPEPACP3PPARGPPARA
SCHEMBL8947039 0.83 LAP3 (0.36) LAP3ANPEPACP3
SCHEMBL8618813 0.82 PPARA (0.37) LAP3ANPEPPPARGPPARATHRB
SCHEMBL8824820 0.82 LAP3 (0.33) LAP3ANPEPPIN1ACP3PPARG
SCHEMBL8947013 0.82 HTR2A (0.35) LAP3ANPEPACP3
SCHEMBL8623433 0.82 SCN4A (0.39) LAP3ANPEPPIN1ACP3PPARG
SCHEMBL8620463 0.78 FDFT1 (0.38) LAP3ANPEPPIN1ACP3PPARG
SCHEMBL8625231 0.78 ACP3 (0.47) LAP3ANPEPACP3PPARGPPARA
SCHEMBL8618892 0.78 LAP3 (0.43) LAP3ANPEPPIN1ACP3PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US claimed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP claimed
US-5567841-A ANTICHOLESTEROL AGENT BRISTOL-MYERS SQUIBB COMPANY (US) 1996-10-22 US disclosed
US-5470845-A Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia BRISTOL-MYERS SQUIBB COMPANY (US) 1995-11-28 US disclosed
EP-0595635-A1 Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors E.R. Squibb & Sons, Inc. (US) 1994-05-04 EP disclosed